

## Product supply shortages addressed for the *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Mylan-Verapamil SR 120 mg Sustained-Release Tablet (DIN 02210347) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 3, 2024**. The following grouping was removed from the Critical Supply Product List **May 2, 2024**.

### VERAPAMIL HCL

#### 120 MG SUSTAINED-RELEASE TABLET

00002246893	APO-VERAP SR	APX	\$ 0.5078
00002210347	MYLAN-VERAPAMIL SR	MYP	\$ 0.5078
00001907123	ISOPTIN SR	BGP	\$ 1.6639

Alberta Blue Cross has confirmed that the shortage for Act Dextroamphetamine SR 10 mg Sustained-Release Capsule (DIN 02448319) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 3, 2024**. The following grouping was removed from the Critical Supply Product List **May 2, 2024**.

### DEXTROAMPHETAMINE SULFATE

#### 10 MG SUSTAINED-RELEASE CAPSULE

00002448319	ACT DEXTROAMPHETAMINE SR	TEV	\$ 0.8096
00001924559	DEXEDRINE	PAL	\$ 1.0060

Alberta Blue Cross has confirmed that the shortage for Act Dextroamphetamine SR 15 mg Sustained-Release Capsule (DIN 02448327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 3, 2024**. The following grouping was removed from the Critical Supply Product List **May 2, 2024**.

### DEXTROAMPHETAMINE SULFATE

#### 15 MG SUSTAINED-RELEASE CAPSULE

00002448327	ACT DEXTROAMPHETAMINE SR	TEV	\$ 0.9898
00001924567	DEXEDRINE	PAL	\$ 1.2299

*continued next page*

# PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortages for ACH-Solifenacin Succinate 5 mg Tablet (DIN 02439344), Auro-Solifenacin 5 mg Tablet (DIN 02446375), Jamp-Solifenacin 5 mg Tablet (DIN 02424339), and PRZ-Solifenacin 5 mg Tablet (DIN 02493039) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 3, 2024**. The following grouping was removed from the Critical Supply Product List **May 9, 2024**.

## SOLIFENACIN SUCCINATE

### 5 MG TABLET

00002439344	ACH-SOLIFENACIN SUCCINATE	AHI	\$ 0.3041
00002446375	AURO-SOLIFENACIN	AUR	\$ 0.3041
00002428911	JAMP SOLIFENACIN SUCCINATE	JPC	\$ 0.3041
00002424339	JAMP-SOLIFENACIN	JPC	\$ 0.3041
00002529696	M-SOLIFENACIN SUCCINATE	MTR	\$ 0.3041
00002417723	PMS-SOLIFENACIN	PMS	\$ 0.3041
00002493039	PRZ-SOLIFENACIN	PCI	\$ 0.3041
00002399032	SANDOZ SOLIFENACIN	SDZ	\$ 0.3041
00002458241	SOLIFENACIN	SNS	\$ 0.3041
00002437988	TARO-SOLIFENACIN	SPG	\$ 0.3041
00002397900	TEVA-SOLIFENACIN	TEV	\$ 0.3041
00002277263	VESICARE	ASP	\$ 1.5135

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

